Results 71 to 80 of about 2,195 (197)
Human Vaccines & Immunotherapeutics, 2021 Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older.
Brandon J. Patterson +5 more
doaj +1 more source
Availability of Shingrix Vaccine in St. Albans and its Benefits vs Zostavax [PDF]
, 2019 Across the United States, including St. Albans, Vermont, a shortage of Shingrix Vaccine has left many patients without effective protection from shingles.
Hussein, Ibrahim Sobhi-Luther
core +1 more source
Australasian Journal of Dermatology, Volume 66, Issue 7, Page e444-e460, November 2025.ABSTRACT Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected individuals experience only a single patch and achieve spontaneous, complete and durable remission within
Daniella Kushnir‐Grinbaum +19 more
wiley +1 more source
Vaccination in Multiple Myeloma: Challenges and Strategies
European Journal of Haematology, Volume 115, Issue 4, Page 334-343, October 2025.ABSTRACT Background Multiple myeloma (MM) is a hematological malignancy characterized by profound immunosuppression resulting from both disease‐related mechanisms and treatment‐induced immune dysfunction. This compromised immune status markedly increases susceptibility to infections, a leading cause of morbidity and mortality in MM patients.
Enrica Antonia Martino +10 more
wiley +1 more source
Shingrix Revaccination and Vaccination in Vulnerable Populations [PDF]
, 2019 Herpes zoster, also known as shingles, is a painful cutaneous eruption that develops following the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox.1 About 1 in 3 people in the United States will develop shingles ...
Andraos, John +2 more
core +1 more source
Populations Addressed in Vaccines Approved via the European Medicines Agency
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 459-469, August 2025.Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf +3 more
wiley +1 more source
Vacina contra o herpes zoster em Portugal
Revista Portuguesa de Medicina Geral e Familiar, 2020 Herpes zoster (HZ), também conhecido por zona, é uma doença causada pela reativação do vírus varicella zoster (VZ). O aumento da idade pode ser um fator de risco para HZ e as suas maiores complicações são a nevralgia pós-herpética (NPH) e o herpes ...
Margarida Gil Conde +1 more
doaj +1 more source
Shingles Vaccine: Identifying high risk groups in the IBD clinic setting [PDF]
, 2019 Title: Shingles Vaccine: Identifying high risk groups in the IBD clinic setting Background: The Inflammatory Bowel Disease (IBD) population is an immunocompromised patient population who is at risk for Herpes Zoster (HZ) due to their medication regimen ...
Barajas, Crystal
core +1 more source
Morphology of Vaccine RD&D translation
, 2023 Translation as a concept coordinates participation in innovation but remains a qualitative construct. We provide multivariate accounting of linkages between market entries of vaccines, clinical trials, patents, publications, funders, and grants to ...
Evans, Tim S +3 more
core
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 8, Page 925-931, August 2025.Zusammenfassung Die immunsuppressive und ‐modulierende Behandlung dermatologischer Patienten macht eine Überprüfung und gegebenenfalls Aktualisierung notwendiger Standard‐ und Indikationsimpfungen erforderlich. Die Ständige Impfkommission (STIKO) am Robert Koch‐Institut veröffentlicht regelmäßig evidenzbasierte Impfempfehlungen, die an die aktuelle ...
Johanna Stoevesandt +3 more
wiley +1 more source